Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 52 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 33.8% in the last three months.
Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $11.50, about 77.6% above its last closing price of $2.58
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.75 | -0.77 | -2.52 | Missed | -225.2 |
2025 | |||||
| |||||
Jun. 30 2024 | -1.61 | -2.41 | -1.15 | Beat | 52.4 |
Mar. 31 2024 | -3.81 | -3.60 | -5.98 | Missed | -66 |
Dec. 31 2023 | -10.66 | -9.84 | -8.28 | Beat | 15.9 |
Sep. 30 2023 | -9.40 | -9.57 | -8.97 | Beat | 6.3 |
Jun. 30 2023 | -9.92 | -10.35 | -11.04 | Missed | -6.7 |
This summary was machine generated August 5 at 14:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。